ENANTA PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 11, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-30; filed 2025-08-13.
0001193125-25-179795
Item 1A. Risk FactorsOther InformationCurrent report: 10-Q
Period ended 2025-12-31; filed 2026-02-11.
0001193125-26-046502
Item 1A. Risk FactorsOther InformationThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 8 previous paragraphs and 5 current paragraphs.
4 unchanged; 1 reworded; 0 added; 3 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Removed paragraphs (3)
Previous report
Rule 10b5-1 Trading Arrangements. During the three months ended June 30, 2025, the officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company set forth below adopted or terminated a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c).
Previous report
On April 16, 2025, Paul J. Mellett, our Chief Financial and Administrative Officer, terminated a previously adopted Rule 10b5-1 trading plan. The plan was originally adopted on June 14, 2024 and scheduled to run through May 30, 2025. No trades were executed under the plan.
Previous report
On June 10, 2025, Jay R. Luly, Ph.D., our President, Chief Executive Officer and Director, adopted a Rule 10b5-1 trading plan providing for the sale of up to 110,000 and 80,000 shares of common stock vested under outstanding stock options, which are set to expire on November 20, 2025 and November 18, 2026, respectively, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between September 9, 2025 and May 29, 2026, or such earlier date as all authorized sales under the plan are completed.
Reworded paragraphs (1)
Previous wording
Except as set forth above, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
Current wording
Rule 10b5-1 Trading Arrangements. During the three months ended December 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.